Wednesday, March 24, 2010

PegIntron® Challenger Zalbin® Advances In Trials

Per Reuters' reporting, this morning -- HGSI's next generation of Hep C treatments, ones that will compete with legacy Schering-Plough's PegIntron® product -- have shown promise in mid-stage trials:

. . . .Human Genome Sciences Inc said interim data from a mid-stage study testing a monthly-dosing version of its experimental hepatitis C treatment, Zalbin®, showed the drug's efficacy was comparable with the current standard of care.

Human Genome and its partner Novartis AG have already submitted an application to the U.S. health regulators for a version of Zalbin dosed every two weeks and received a review date of October 4, 2010. . . .

The two current leading interferons, Pegasys and Merck's Pegintron are taken intravenously [sic; Ed. Note (per comment below) -- in fact, these medicines are self-injected, not "dripped" by IV bag] once a week for up to 48 weeks in combination with the antiviral pill ribavirin, while Zalbin is injected [only once] every two weeks.

Human Genome shares were up 1 percent to $32.55 in premerket trade. They had closed at $32.10 Tuesday on NASDAQ. . . .



Anonymous said...

PegIntron is not an IV drug, it is self injected.

condor said...

Good catch -- it is thus -- in the original press report.

I'll put a bracketed note into mine, now.